Table 1.
Demographics and baseline characteristics of patients at iBox risk evaluation
| N | EVR+rCNI N=940 |
MPA+sCNI N=932 |
P value | |
| Recipients’ characteristics | ||||
| Age, n (%) | 1871 | 0.571 | ||
| 18–30 years | 633 | 328 (34.9) | 305 (32.7) | |
| 31–55 years | 1065 | 529 (56.3) | 536 (57.6) | |
| 56–80 years | 173 | 83 (8.8) | 90 (9.7) | |
| Male sex | 652 (69.4) | 646 (69.3) | 0.982 | |
| Cold ischaemia time, hours, mean (SD) | 1859 | 8.1 (7.7) | 8.2 (7.7) | 0.820 |
| Delayed graft function, n (%) | 174 | 93 (9.9) | 81 (8.7) | 0.370 |
| HLA-A/B/DR mismatch, mean (SD) | 1862 | 3.4 (1.5) | 3.4 (1.5) | 0.620 |
| Type of CNI, n (%) | 1868 | 0.836 | ||
| Tacrolimus | 846 (90.4) | 845 (90.7) | ||
| Cyclosporine | 90 (9.6) | 87 (9.3) | ||
| Induction, n (%) | 1871 | 0.795 | ||
| Basiliximab | 789 (84.0) | 779 (83.6) | ||
| rATG | 150 (16.0) | 153 (16.4) | ||
| ESRD leading to transplant | 1872 | 0.885 | ||
| Glomerulonephritis | 144 (15.3) | 154 (16.5) | ||
| Diabetes | 118 (12.6) | 120 (12.9) | ||
| Hypertension/nephrosclerosis | 115 (12.2) | 114 (12.2) | ||
| Other | 427 (45.4) | 423 (45.4) | ||
| Unknown | 136 (14.5) | 121 (13.0) | ||
| Donor characteristics, n (%) | ||||
| Male sex | 869 | 423 (48.9) | 446 (51.4) | 0.291 |
| Donor category | 1717 | 0.329 | ||
| Living related | 270 (31.6) | 249 (28.9) | ||
| Living unrelated | 173 (20.2) | 161 (18.7) | ||
| Deceased non-heart beating | 3 (0.4) | 5 (0.6) | ||
| Deceased heart beating | 409 (47.8) | 447 (51.8) | 0.084 | |
| Standard criteria donor | 295 (72.1) | 298 (66.7) | ||
| Expanded criteria donor | 114 (27.9) | 149 (33.3) |
CNI, calcineurin inhibitor; ESRD, end-stage renal disease; EVR, everolimus; HLA, human leucocyte antigen; iBox, integrative Box; MPA, mycophenolic acid; rATG, rabbit antithymocyte globulin; rCNI, reduced-exposure CNI; sCNI, standard-exposure CNI.